GSK plc Stock Deutsche Boerse AG

Equities

GS71

GB00BN7SWP63

Pharmaceuticals

Real-time Estimate Tradegate 12:25:35 2024-06-12 pm EDT 5-day change 1st Jan Change
19.12 EUR +0.75% Intraday chart for GSK plc +1.12% +16.73%

Financials

Sales 2024 * 31.66B 40.68B 37.5B Sales 2025 * 33.63B 43.2B 39.83B Capitalization 65.86B 84.6B 78.01B
Net income 2024 * 5.57B 7.16B 6.6B Net income 2025 * 6.52B 8.37B 7.72B EV / Sales 2024 * 2.47 x
Net Debt 2024 * 12.23B 15.71B 14.48B Net Debt 2025 * 8.75B 11.24B 10.37B EV / Sales 2025 * 2.22 x
P/E ratio 2024 *
11.7 x
P/E ratio 2025 *
10.1 x
Employees 70,212
Yield 2024 *
3.76%
Yield 2025 *
3.9%
Free-Float 94.54%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.79%
1 week+1.12%
Current month-4.95%
1 month-7.48%
3 months-1.14%
6 months+15.30%
Current year+16.73%
More quotes
1 week
18.98
Extreme 18.975
19.53
1 month
18.55
Extreme 18.55
21.57
Current year
16.48
Extreme 16.482
21.57
1 year
15.24
Extreme 15.242
21.57
3 years
14.62
Extreme 14.62
27.13
5 years
14.62
Extreme 14.62
27.52
10 years
14.62
Extreme 14.62
28.69
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 10-04-30
Director of Finance/CFO 62 23-04-30
Compliance Officer - 95-07-31
Members of the board TitleAgeSince
Director of Finance/CFO 62 23-04-30
Chairman 66 19-08-31
Director/Board Member 62 17-12-31
More insiders
Date Price Change Volume
24-06-12 19.48 +2.64% 2 050
24-06-11 18.98 -0.50% 545
24-06-10 19.07 +0.37% 233
24-06-07 19 -0.03% 0
24-06-06 19 -1.32% 170

Delayed Quote Deutsche Boerse AG, June 12, 2024 at 09:35 am EDT

More quotes
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
16.15 GBP
Average target price
20.36 GBP
Spread / Average Target
+26.10%
Consensus